Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

Marian Iwamoto, Larissa A Wenning, Goutam C Mistry, Amelia S Petry, Sarah Y Liou, Kaylan Ghosh, Sheila Breidinger, Neal Azrolan, Maria J Gutierrez, William E Bridson, Julie A Stone, Keith M Gottesdiener, John A Wagner

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47(1):137-40

PMID: 18513146

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir.

Address: Merck, Whitehouse Station, RY34-A500, PO Box 2000, Rahway, NJ 07065-0900, USA. [email protected]

DOI: 10.1086/588794

Link outs

Free resources

Medical:

https://medlineplus.gov/hivmedicines.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Anti-HIV Agents, Atazanavir Sulfate, Double-Blind Method, Female, Humans, Male, Oligopeptides, Organic Chemicals, Placebos, Plasma, Pyridines, Pyrrolidinones, Raltegravir Potassium